Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 2
1966 1
1967 5
1969 4
1970 2
1972 2
1973 7
1974 5
1975 4
1976 6
1977 1
1978 1
1979 2
1980 1
1981 3
1982 4
1984 2
1985 3
1986 1
1987 5
1988 1
1989 2
1990 3
1991 1
1992 9
1993 5
1994 1
1995 2
1996 1
1997 4
1998 8
1999 16
2000 6
2001 10
2002 5
2003 14
2004 8
2005 11
2006 14
2007 11
2008 13
2009 16
2010 14
2011 15
2012 14
2013 24
2014 12
2015 15
2016 13
2017 11
2018 13
2019 7
2020 24
2021 12
2022 12
2023 18
2024 12

Text availability

Article attribute

Article type

Publication date

Search Results

397 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials.
Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C, Figueroa MS, Lin H, Holz FG, Patel V, Lai TYY, Silverman D, Regillo C, Swaminathan B, Viola F, Cheung CMG, Wong TY; TENAYA and LUCERNE Investigators. Heier JS, et al. Lancet. 2022 Feb 19;399(10326):729-740. doi: 10.1016/S0140-6736(22)00010-1. Epub 2022 Jan 24. Lancet. 2022. PMID: 35085502 Clinical Trial.
Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials.
Wykoff CC, Abreu F, Adamis AP, Basu K, Eichenbaum DA, Haskova Z, Lin H, Loewenstein A, Mohan S, Pearce IA, Sakamoto T, Schlottmann PG, Silverman D, Sun JK, Wells JA, Willis JR, Tadayoni R; YOSEMITE and RHINE Investigators. Wykoff CC, et al. Lancet. 2022 Feb 19;399(10326):741-755. doi: 10.1016/S0140-6736(22)00018-6. Epub 2022 Jan 24. Lancet. 2022. PMID: 35085503 Clinical Trial.
Reply.
Figueroa MS, Govetto A, Contreras I, Ruiz-Moreno JM, del Valle FG, Plascencia RN, Medina JL. Figueroa MS, et al. Among authors: ruiz moreno jm. Retina. 2016 Jan;36(1):e4-5. doi: 10.1097/IAE.0000000000000915. Retina. 2016. PMID: 26702607 No abstract available.
Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials.
Wong TY, Haskova Z, Asik K, Baumal CR, Csaky KG, Eter N, Ives JA, Jaffe GJ, Korobelnik JF, Lin H, Murata T, Ruamviboonsuk P, Schlottmann PG, Seres AI, Silverman D, Sun X, Tang Y, Wells JA, Yoon YH, Wykoff CC; YOSEMITE and RHINE Investigators. Wong TY, et al. Ophthalmology. 2024 Jun;131(6):708-723. doi: 10.1016/j.ophtha.2023.12.026. Epub 2023 Dec 28. Ophthalmology. 2024. PMID: 38158159 Free article. Clinical Trial.
Reply.
Ruiz-Moreno JM, Montero JA. Ruiz-Moreno JM, et al. Retina. 2016 Jun;36(6):e51. doi: 10.1097/IAE.0000000000001079. Retina. 2016. PMID: 27145258 No abstract available.
TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2.
Khanani AM, Kotecha A, Chang A, Chen SJ, Chen Y, Guymer R, Heier JS, Holz FG, Iida T, Ives JA, Lim JI, Lin H, Michels S, Quezada Ruiz C, Schmidt-Erfurth U, Silverman D, Singh R, Swaminathan B, Willis JR, Tadayoni R; TENAYA and LUCERNE Investigators. Khanani AM, et al. Ophthalmology. 2024 Feb 19:S0161-6420(24)00134-9. doi: 10.1016/j.ophtha.2024.02.014. Online ahead of print. Ophthalmology. 2024. PMID: 38382813 Free article.
Myopic choroidal neovascularization.
Ruiz-Moreno JM, López-Gálvez MI, Donate J, Gomez-Ulla F, García-Arumí J, García-Layana A, Sellés I, Reche J, Montero JA, Pazos B, Zapata MA, Pastor JC. Ruiz-Moreno JM, et al. Ophthalmology. 2011 Dec;118(12):2521-3. doi: 10.1016/j.ophtha.2011.07.029. Ophthalmology. 2011. PMID: 22136676 Clinical Trial. No abstract available.
397 results